NovoCure Limited
15.63USD
-1.2200 (-7.24%)
Computing valuation metrics…
Valuation
P/E (TTM)
—
P/E (Forward)
—
EV/EBITDA
—
EV/Revenue
2.51x
P/S (TTM)
2.81x
P/B
5.80x
FCF Yield
-1.30%
Dividend Yield
0.00%
Gross Margin
76.13%
Operating Margin
-22.08%
Net Margin
-21.25%
Peer Comparison — Medical Devices
| Company | Mkt Cap | P/E | EV/EBITDA | FCF Yield | Rev Growth | Div Yield |
|---|---|---|---|---|---|---|
| NVCRNovoCure Limited | $1.96B | — | — | -1.30% | 15.60% | 0.00% |
| ABTAbbott Laboratories | $182.09B | 34.06x | 18.01x | 3.96% | 13.00% | 2.39% |
Subject metrics from SEC filings where available; peer metrics from cached market data.
| $118.18B |
| 22.76x |
| 13.49x |
| 4.58% |
| 13.70% |
| 3.06% |
| SYKStryker Corporation | $106.03B | 28.68x | 17.39x | 3.87% | 9.40% | 1.16% |
| BSXBoston Scientific Corporation | $65.19B | 18.21x | 13.57x | 3.76% | 7.50% | — |
| EWEdwards Lifesciences Corporation | $49.99B | 51.62x | 24.23x | 2.47% | 13.60% | — |
| DXCMDexCom, Inc. | $31.90B | 33.41x | 22.34x | 3.20% | 13.10% | — |
| GEHCGE HealthCare Technologies Inc. | $30.16B | 15.39x | 10.82x | 5.22% | 5.80% | 0.20% |
| STESTERIS plc | $21.30B | 26.70x | 13.94x | 3.75% | 7.30% | 1.15% |